1. Lloyd-Jones, D.M., et al., Lifetime Risk for Developing Congestive Heart
Failure: The Framingham Heart Study. Circulation, 2002. 106(24): p. 3068-3072.
2. McMurray, J.J. and S. Stewart, Epidemiology, aetiology, and prognosis of heart failure. Heart, 2000. 83(5): p. 596-602.
3. Brown, A.M. and J.G.F. Cleland, Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. European Heart Journal, 1998. 19(7): p. 1063-1069.
4. Cleland, J.G., et al., The Euro Heart Failure Survey of the EUROHEART surve yprogramme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail, 2000. 2(2): p. 123-32.
5. Banerjee, P., et al., Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol, 2002. 39(1): p. 138-41.
6. Banerjee, P., et al., Diastolic heart failure. Paroxysmal or chronic? Eur J Heart Fail, 2004. 6(4): p. 427-31.
7. Khand, A., et al., Is the prognosis of heart failure improving? J Am Coll Cardiol,2000. 36(7): p. 2284-6.
8. Cleland, J.G., et al., Is the prognosis of heart failure improving? Eur J Heart Fail,1999. 1(3): p. 229-41.
9. Yusuf, S., et al., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet,2003. 362(9386): p. 777-81.
10. Pfeffer, M.A., et al., Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003. 362(9386): p. 759-66.
11. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med, 1992. 327(10): p. 685-691.
12. Mehta, P.A., et al., Mode of death in patients with newly diagnosed heart failure in the general population. European Journal of Heart Failure, 2008.10(11): p. 1108-1116.
13. Davies, M. and A. Thomas, Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med, 1984. 310(18): p. 1137-1140.
14. Uretsky, B.F., et al., Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death : Results From the Assessment of Treatment With Lisinopril and Survival (ATLAS) Trial. Circulation, 2000. 102(6): p. 611-616.
15. Kober, L., et al., A Clinical Trial of the Angiotensin-Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med, 1995. 333(25): p. 1670-1676.
16. Pfeffer, M., et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med,1992.327(10): p. 669-677.
17. Effect of carvedilol on outcome after myocardial infarction in patients with left- ventricular dysfunction: the CAPRICORN randomised trial. The Lancet,2001.357(9266): p. 1385-1390.
18. Pitt, B., et al., Eplerenone, a Selective Aldosterone Blocker, in Patients with LeftVentricular Dysfunction after Myocardial Infarction. N Engl J Med,2003.348(14): p. 1309-1321.
19. Packer, M., et al., The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med, 1996. 334(21): p. 1349-1355.
20. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. TheLancet, 1999. 353(9146): p. 9-13.
21. O'Connor, C.M., et al., Effect of amlodipine on mode of death among patients with advanced heart failure in the praise trial. The American Journal of Cardiology, 1998. 82(7): p. 881-887.
22. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XLRandomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). TheLancet, 1999. 353(9169): p. 2001-2007.
23. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med, 1987. 316(23): p. 1429-1435.
24. Pitt, B., et al., The Effect of Spironolactone on Morbidity and Mortality inPatients with Severe Heart Failure. The New England Journal of Medicine, 1999. 341(10): p. 709-717.
25. Huikuri, H.V., et al., Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation, 2003.108(1): p. 110-5.
26. Huikuri, H.V., A. Castellanos, and R.J. Myerburg, Sudden death due to cardiac arrhythmias. N Engl J Med, 2001. 345(20): p. 1473-82.
27. Zipes, D.P. and H.J. Wellens, Sudden cardiac death. Circulation, 1998. 98(21): p.2334-51.
28. Deedwania, P.C., The Key to Unraveling the Mystery of Mortality inHeartFailure: An Integrated Approach. Circulation, 2003. 107(13): p. 1719-1721.
29. Bunch, T.J., S.H. Hohnloser, and B.J. Gersh, Mechanisms of Sudden Cardiac Death in Myocardial Infarction Survivors: Insights From the Randomized Trials of Implantable Cardioverter-Defibrillators. Circulation, 2007. 115(18): p. 2451-2457.
30. La Rovere, M.T., et al., Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias : Implications for Clinical Trials. Circulation, 2001. 103(16): p. 2072-2077.
31. Dobson, C.P., et al., 24-hour QT variability in heart failure. J Electrocardiol,2009. 42(6): p. 500-4.
32. Stevenson, W.G. and L.M. Epstein, Predicting Sudden Death Risk forHeartFailure Patients in the Implantable Cardioverter-Defibrillator Age. Circulation, 2003. 107(4): p. 514-516.
33. Nolan, J., et al., Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure : Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart). Circulation, 1998.98(15): p. 1510-1516.
34. Bode-Schnurbus, L., et al., QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. Heart, 2003. 89(10): p.1157-1162.
35. Berger, R., et al., B-Type Natriuretic Peptide Predicts Sudden Death in PatientsWith Chronic Heart Failure. Circulation, 2002. 105(20): p. 2392-2397.